TORAY INDUSTRIES INC.

Japan's Intellectual Property High Court Orders ¥21.7 Billion Patent Infringement Payout for Toray's Anti-Itch Drug

- Japan's Intellectual Property High Court ordered Sawai Pharmaceutical and Fuso Pharmaceutical Industries to pay a combined ¥21.7 billion in compensation for patent infringement of Toray's nalfurafine-based anti-itch medication. - Sawai Pharmaceutical was ordered to pay ¥14.29 billion while Fuso Pharmaceutical Industries must pay ¥7.47 billion for manufacturing and selling generic versions of the drug containing nalfurafine. - The case centers on Toray's 2017 patent extension application for nalfurafine as an itch-alleviating treatment, with both companies launching generic versions in 2018 by mixing additives with the active ingredient. - Both infringing companies have indicated plans to challenge the ruling, with Fuso announcing its intention to appeal to Japan's Supreme Court.